Callisto Pharmaceuticals
New reports from Callisto Pharmaceuticals detailed
Published in Physician Law Weekly, May 9th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Callisto Pharmaceuticals.
Report 1: Callisto Pharmaceuticals, Inc., (KAL; CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced the opening of a second clinical site, the Dana-Farber Cancer Institute in Boston, Massachusetts, for its phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine carcinoma (advanced carcinoid cancer).
The Principal Investigator at the Dana-Farber Cancer Institute is...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
Source: Physician Law Weekly (2007-05-09)
More Articles from Physician Law Weekly
- Acne Vulgaris
TopoTarget announces next Phase II clinical placebo controlled trial with Avugane in acne vulgaris - Alzheimer Disease
Memory Ride for Alzheimer's Research Set July 28th - American Occupational Therapy Association
Military Occupational Therapy Helps Wounded Warriors and Civilians Alike - Amerinet Inc.
Hospitals To Utilize Diagnostix's Industry-Driven Pharmacy Technology - Angioplasty
Abiomed Completes Enrollment of Pilot Clinical Trial for Impella 2.5 Circulatory Support System - Back Pain
Backbone of Success: NP Solutions Wins Wharton Business Plan Competition Grand Prize with Next Generation Back Pain Treatment - More from this issue of Physician Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
